Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

Congress
Main Content

2024 Research Protocol Abstracts

Poster Hall (Exhibit Hall A)
10:00 - 17:30

 

Saturday, September 28

93- 18F-Florzolotau PET uncovers the Co-pathological Heterogeneity of Tau Protein in Dementia with Lewy Bodies
407- EEG Profiles in People with Functional Movement Disorders Before and After a Single Bout of Hatha Yoga and Moderate-vigorous Intensity Aerobic Exercise: A Protocol for a Pilot Feasibility Study
459- PREVENT-PD: A Framework for Collecting Trichloroethylene Contamination Data in New York State
545- Cross-cultural adaptation to Argentine Spanish and validation of the High Level Mobility Assessment Tool in individuals with Parkinson's disease
549- ProACT Study Protocol: a Randomized, Wait-list Controlled, Pragmatic Study on Parkinson's Disease Multimodal Complex Treatment
 

Sunday, September 29

626- SAGE-324/BIIB124, an investigational GABAA receptor PAM, for treatment of essential tremor
636- ORION: A Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009)
639- A Phase 1b Randomized, Placebo-Controlled, Delayed-Start Trial of UB-312 in Synucleinopathies
640- Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS). A Phase II clinical trial - ISRCTN99462035.
641- Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide
643- A Randomized, Double-blind, Phase 2a Clinical Trial to Study the Efficacy and Safety of Lamotrigine for Treatment of Patients with Dementia with Lewy Bodies
682- REGENERATE-PD: A Phase 2, Randomized, Double-Blind, Surgery-Controlled Study of GDNF Gene Therapy (AAV2-GDNF; AB-1005) for Moderate Stage Parkinson’s Disease
702- GRoningen Early-PD Ambroxol Treatment (GREAT) Trial: A randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA-mutation
703- WATCH-PD2: A Remote Extension Digital Measures Study in Early Parkinson’s Disease: Study Design and Status Update
704- The HIIT-Home4Parkinson’s study
717- Selecting an Imaging Biomarker for a Multi-Arm Multi-Stage Trial of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Experience
722- Rationale and Design of the Slowing Parkinson’s Early through Exercise Dosage – United Kingdom (Slow-SPEED-UK) Trial
728- Developing a selection framework for digital measures of Parkinson’s disease progression for the EJS ACT-PD trial
730- Comparing Ring and Directional Globus Pallidus Stimulation Effects on Parkinson’s Gait
733- PD-DigiCare: Enhancing referral decision-making for advanced treatment in Parkinson's Disease through objective measurements and patient reported outcomes - a multicenter randomized controlled trial
737- Clinic vs Self-Referral for a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo in Patients with Neurodegenerative Parkinsonism
738- The Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder (RBD)
742- LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson’s disease:  Study Design to Evaluate Safety, Pharmacodynamics and Pharmacokinetics
746- A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease (PADOVA): Rationale, Design, and Baseline Data
762- First-In-Human Single and Multiple Ascending Dose Trial Design of LY3962681, a Novel Intrathecally Delivered siRNA Targeting α-synuclein mRNA for the Treatment of Patients with Parkinson’s Disease
928- Rationale for LRRK2 inhibition in sporadic Parkinson’s disease and the LUMA trial
1133- Safety and effectiveness of staged bilateral MR-guided focused ultrasound pallidothalamic tractotomy for motor complications of Parkinson’s disease: study protocol
 

Monday, September 30

1416- The Yips in Golf: Is it a Task-Specific Dystonia ?
1439- Investigating Impaired Perceptual Decision Making in Cervical Dystonia: A novel paradigm integrating Behavioural and Neural measures
1459- Non-motor symptoms in people with Huntington's disease: use and validation of the MDS Non-Motor Scale (MDS-NMS)
1563- Assessing the Economic Impact of Transcutaneous Afferent Patterned Stimulation Therapy for Essential Tremor: A Real-World Evidence Study Protocol
1644- Understanding the earliest phases of Parkinson’s disease (PD) -  an expanding opportunity to study ‘at-risk’/early/prodromal PD in the Global Parkinson’s Genetics Program (GP2)
1655- Studying monogenic Parkinson’s disease by building a global cohort of mutation carriers
1672- Expanding the PD GENEration Study to increase clinical genetic testing and counseling using whole genome sequencing among diverse Parkinson’s disease (PD) populations
1676- Expanding Diversity of Parkinson’s Disease and Related Disorders Genetic Data: from the Global Parkinson’s Genetics Program
1677- Determining and Leveraging Local Ancestry to Assess Individual-Level Risk: from the Global Parkinson’s Genetics Program
1858- What you should know about your patient
1864- EMPOWER-PD: Testing and evaluation of an 8-week co-created Self-management program tailored People with Parkinson`s disease and their caregivers in an interventional follow-up study
1885- Utility of Serum α-synuclein Seed Amplification Assay as a Parkinson’s Disease Biomarker
1891- The Pro-LBD Study Investigating Early Detection, Prognosis, and Biomarkers of Prodromal Lewy Body Disease 

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice